Inclement weather, strong product performances and the impact of M&A all help to drive another quarter of healthy growth for the Trauma Market.

The Trauma Market experienced the third sequential quarter of increasingly healthy growth as both the WW and US Trauma Markets were up YoY. New product introductions, along with inclement weather in the US and EU drove trauma procedures during the first quarter of 2021.

During the Stryker Q121 earnings call, management noted that their trauma business, which is less elective in nature, benefited from inclement weather in the US and Europe in February. 

Among the many topics covered in detail in our comprehensive Q121 Trauma Market Recap* are:

Healthy growth closes out Q420 as the trauma segment recovers in the second half of the year hitting pre-COVID levels.

Despite the rise in COVID cases during Q4, the Trauma Market fared well resulting in positive YoY revenue gains that represented healthy, pre-COVID level volumes. Trauma players cited another quarter of healthy trauma growth, as the second half of the year ended on an upswing (+5.6% vs. H219). Top US market leaders, DePuy Synthes (49.4% Q420 US share), Stryker (27.3%) and Smith & Nephew (9.8%) all reported improved sequential gains.

Among the many topics covered in the comprehensive Q420/FY20 Trauma Market Recap* are:

As companies ride the latest wave of COVID-19, SmartTRAK predicts the trends and technologies that will continue to advance the trauma industry in 2021 and 2022.

Trend #1: Procedures Return to Near-Normal Levels in 2021

After the first swell of COVID-19 this past March, elective surgeries took a major hit. As most procedures were postponed during this phase of the pandemic, the trauma segment was impacted to a lesser extent. In early 2020, trauma surgeons reported seeing definite decreases in volumes due to stay-at-home orders, with polytrauma being almost negligible in certain US cities. Geriatric fractures also decreased, but to a lesser extent according to the OTA COVID-19 Webinar discussion. Despite the decrease, surgeons treated the majority of trauma fracture fixation procedures and provided conservative treatment in only a small portion of patients who were in facilities or areas heavily impacted by COVID-19.

With restrictions lifted during Q320, the trauma segment rebounded from the prior quarter as procedural volumes increased and revenues hit pre-COVID levels.

In the absence of strict COVID restrictions, the jump ball went to the return of healthy trauma volumes during Q320. Major players cited quarterly growth in line with previous years. Q320 picked up the pace with the US Trauma Market leading the charge, up +4.6%, while the EU and ROW declined.

Among the many topics, including company revenues, shares, charts and expert analysis, covered in the comprehensive Q320 Trauma Market Recap* are:

COVID-19 halts the Trauma Market’s Q120 growth, leading to a -2.8% YoY decline globally.

Q120 was tracking as a stable quarter for the US Trauma Market, following Q419’s +3.8% growth, however, this was interrupted in mid-March by the COVID-19 pandemic. The US Trauma Market was down -1.2% YoY for the quarter, with WW revenues declining -2.8%. The non-elective trauma market experienced a reduction in trauma admissions due to the decrease in daily activities and limited driving for most of the US.

Among the many topics covered in the comprehensive Q120 Trauma Market Recap* are:

Tough comps and pricing pressure dampen growth during Q419

According to BioMedGPS’ SmartTRAK Financial Dashboard, the WW Trauma Market posted +2.8% growth, down from Q3, while the US achieved growth of +3.8%, also down from Q3. Trauma market leader DePuy Synthes (48.6% US Q4 share) reported while sales were down compared to Q319, gains were driven by overall market growth and strong adoption of their Femoral Neck System.

Tough comparisons, both YoY and sequentially, impacted the Q419 Trauma Market. The US pricing environment remains relatively steady as DePuy Synthes noted pricing pressure of -2.0%, in line with their Q2 and Q3 pricing (Q1 was -2.5%). Zimmer Biomet’s SET pricing improved in Q4 at -1.8% vs. Q3’s -2.0%. BioMedGPS believes 2019 pricing trended at -2.0 to -2.5%.

Among the many topics covered in the comprehensive Q419/FY19 Trauma Market Recap* are:

Easy YoY comps along with new product introductions help drive sequential growth 

SmartTRAK reports that In Q319, the WW Trauma Market (defined as fixation of the pelvis, femur & proximal/shaft portion of the tibia) increased +3.7% (as reported), with the US posting +4.6% growth. Q319 WW share leaders remained relatively steady compared to last year, with top trauma player DePuy Synthes, followed by Stryker, Zimmer Biomet and Smith & Nephew. The WW Trauma Market Segment shares were...

Among the many topics covered in the complete, comprehensive  Q319 Trauma Market Recap*  are:

New products help drive sequential improvement in growth 

The WW Market for Foot & Ankle Fixation exceeded $, up +3.9%, as reported, during Q319, up sequentially due to easy YoY comps. The US Foot & Ankle Fixation market also experienced a sequential increase, resulting in +4.3% reported growth. Major players reported improved growth while smaller players announced new product introductions throughout the quarter.

Stryker posted accelerated trauma & extremities growth in Q319,
reaching $, up +9.3% in the foot & ankle fixation segment according to SmartTRAK Financial Dashboard. The foot & ankle powerhouse reported US growth was positively impacted by double-digit growth across foot, ankle and shoulder products along with the T2 Alpha Nails. Stryker recouped lost share from Q2, gaining ~4.4% share to close Q3 at 25.6%. This gain allowed Stryker to take over the number one position from...

Among the many topics covered in the complete, comprehensive Q319 Extremities Market Recap* are:

SmartTRAK Interviews Carl Hasselman, MD about Arthrosurface’s alternative to toe fusions

Arthrosurface showcased its new BOSS Toe Fixation System at the American Orthopaedic Foot & Ankle Society’s (AOFAS 2019) Annual Meeting held September 11–15 in Chicago, IL. Recently 510k cleared, the system improves stabilization in a first metatarsal with a distal bone void. The Boss Toe Screw fills the current product gap in implant solutions for failed synthetic implants. The system provides an option for patients who want to avoid a toe fusion while regaining motion and enjoying an active lifestyle.

To find out more about the new BOSS Toe Fixation System, its benefits, and how it fits in Arthrosurface’s existing line of HemiCAP DF implants and ToeMotion Systems, SmartTRAK interviewed Carl Hasselman, MD, University of Pittsburgh Medical Center, at AOFAS 2019.

To listen to SmartTRAK’s interview with Dr. Hasselman, click on the following video (11:14 minutes). A transcript of the interview is also provided below.

Trauma segment experiences slight sequential gains as product intros gain traction and companies overcome supply disruption.

The WW Trauma Market ended Q2 posting +1.5% (reported) growth, with the US Market driving growth up 3.6% YOY, slightly up sequentially compared to Q1’s 3.2% gains. Internationally, Europe and ROW fared worse due to missed tenders, with -2.1% and -1.1% growth, respectively. Looking forward, SmartTRAK anticipates the trauma segment will see...

Among the many topics covered in the complete Q219 Trauma Market Recap* are: